Loss of OBSCN expression promotes bladder cancer progression but enhances the efficacy of PD-L1 inhibitors
This study confirmed that BLCA patients with low OBSCN expression had a worse prognosis but a superior response to ICIs, providing a reference for individualised treatment of BLCA patients.
Authors
- Tuanjie Guo (ORCID: https://orcid.org/0000-0002-4954-4928)
- Chuanmin Chu
- Xinyue Zang
- Siteng Chen (ORCID: https://orcid.org/0000-0002-5150-7536)
- Mingyue Tan
- Lei Dong (ORCID: https://orcid.org/0000-0001-9574-0148)
- Dongliang Xu
- Sicong Ma (ORCID: https://orcid.org/0000-0002-2233-9967)
- Chaofu Wang (ORCID: https://orcid.org/0000-0002-5956-9328)
- Xiang Wang (ORCID: https://orcid.org/0000-0002-5211-7206)
- Tao Wang (ORCID: https://orcid.org/0000-0002-4918-3915)
- Jian Zhang (ORCID: https://orcid.org/0000-0002-4966-2086)
- Juanjuan Sun (ORCID: https://orcid.org/0000-0002-2264-7732)
- Guihua Chen (ORCID: https://orcid.org/0000-0001-9776-8515)
- Xinyu Zhai
Institutions
- Shanghai Jiao Tong University (CN)
- Renji Hospital (CN)
- Ruijin Hospital (CN)
- Shanghai University of Traditional Chinese Medicine (CN)
- Shanghai First People's Hospital (CN)
- Shuguang Hospital (CN)
- YangPu Geriatric Hospital (CN)
Publication Details
- Journal
- Cell & Bioscience
- Published
- 2025-03-27
- DOI
- https://doi.org/10.1186/s13578-025-01379-w
- Citations
- 2
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 4.01
Funders
- National Natural Science Foundation of China